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ABSTRACT 
 
 
Cryptosporidium parvum is a water-borne and food-borne apicomplexan pathogen. It is one of 
the top four diarrheal-causing pathogens in children under the age of five in developing 
countries, and an opportunistic pathogen in immunocompromised individuals. The preventative 
measures are not fully effective with, nitazoxanide (NTZ), the only FDA-approved drug for use 
in immunocompetent individuals. Unlike other apicomplexans, C. parvum lacks Kreb’s cycle 
and cytochrome-based respiration, thus relying mainly on glycolysis to produce ATP. In this 
study, we characterized the primary biochemical features of the C. parvum glucose-6-phosphate 
isomerase (CpGPI) and determined its Michaelis constant towards fructose-6-phosphate (Km = 
0.309 mM, Vmax = 31.72 nmol/μg/min). We also discovered that ebselen, an organoselenium 
drug, was an inhibitor of CpGPI by high-throughput screening of 1,200 known drugs. Ebselen 
acted on CpGPI as an allosteric noncompetitive inhibitor (IC50 = 8.33 μM), while complete 
inhibition of CpGPI activity was not achieved. Although ebselen is useful in studying the 
inhibition of CpGPI enzyme activity, further proof is needed to chemically and/or genetically 
validate CpGPI as a drug target. We also identified four drugs as CpHK inhibitors with 
micromolar level of anti-cryptospordial activities at concentrations nontoxic to the host cells 
(i.e., hexachlorphene, thimerosal, alexidine dihydrochloride and ebselen with EC50 = 0.53, 1.77, 
8.1 and 165 μM, respectively). The anti-CpHK activity of the four existing drugs provided us 
new reagents for studying the enzyme properties of the parasite hexokinase. We have previously 
observed that 2-deoxy-D-glucose (2DG) could inhibit both the enzyme activity of C. parvum 
hexokinase (CpHK) and the parasite growth in vitro.  However, the action and fate of 2DG in C. 
parvum was not fully investigated. In the present study, we showed that, although 2DG could be 
phosphorylated by CpHK to form 2DG-6-phosphate (2DG6P), the anti-cryptosporidial activity 
iii 
 
of 2DG was mainly attributed to the action of 2DG on CpHK, rather than the action of 2DG or 
2DG6P on the downstream enzyme CpGPI, nor 2DG6P on CpHK. These observations further 
supported the hypothesis that CpHK could serve as a drug target in the parasite.  
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NOMENCLATURE 
  
 
     ACC                            Acetyl-CoA carboxylase 
 
     AceCL                         Acetic acid-CoA ligase 
 
ACL Acyl-CoA Ligase 
 
ADE Aldehyde deydrogenase 
 
      ADH1                         Alcohol dehydrogenase 1 
 
AIDS Acquired Immune Deficiency Syndrome 
 
AMP Adenosine Monophosphate 
 
ATP Adenosine Triphosphate 
 
CD4 Cluster of Differentiation 4 
 
CD8 Cluster of Differentiation 8 
 
CDC Centers for Disease Control and Prevention 
 
CoA Coenzyme A 
 
COWP Cryptosporidium Oocyst Wall Protein 
 
CTP Cytidine Triphosphate 
 
DG                               Deoxy-glucose 
 
DG6P                           Deoxy-glucose-6 phosphate 
 
DMSO Dimethyl Sulfoxide 
 
DNA Deoxyribonucleic Acid 
 
DTT Dithiothreitol 
 
     Ebs                                  Ebselen 
 
FBS Fetal Bovine Serum 
 
F6P                              Fructose-6 phosphate 
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FDA Food and Drug Administration 
 
    GDBE                         Glycogen debranching enzyme 
 
gDNA Genomic Deoxyribonucleic Acid 
 
     GP                              Glycogen phosphorylase 
 
GTP Guanosine Triphosphate 
 
G6P                             Glucose -6phosphate 
 
G6PDH                        Glucose-6- phosphate dehydrogenase 
 
HAART Highly-Active Anti-Retroviral Therapy 
 
HCT-8 Human Colonic Tumor 8 
 
HK                               Hexokinase 
 
HIV Human Immunodeficiency Virus 
 
Hs                                Homo sapiens 
 
ICZN Code of Zoological Nomenclature 
 
IFN-γ Interferon Gamma 
 
IL-12 Interleukin 12 
 
IPTG Isopropyl-1-Thio-β-D Galactopyranoside  
 
     LDH                           Lactic acid dehydrogenase 
 
MBP Maltose Binding Protein 
 
MDH                           Malate dehydrogenase 
 
MHC Major Histocompatibility Complex 
 
MTT Methylthiazol Tetrazolium 
 
NCBI National Center for Biotechnology Information 
 
NIH National Institutes of Health 
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NTP Nucleoside Triphosphates 
 
NTZ Nitazoxanide 
 
ORF Open Reading Frame 
 
PAGE Polyacrylamide Gel Electrophoresis 
 
PBS Phosphate Buffered Saline 
 
PEP                             Phospho-enol pyruvate 
 
PCR Polymerase Chain Reaction 
 
PDC                            Pyruvate decarboxylase 
 
     PGI                             Phosphoglucose isomerase 
 
     PGluM                        Phosphoglucose mutase 
 
PI Post-Infection 
 
PK                                Pyruvate kinase 
 
PMI                            Phosphomannose isomerase 
 
PNO                           Pyruvate:NADP+ oxidoreductase 
 
PPi-PFK                    Pyrophosphate-dependent phosphofructokinase. 
 
PV Parasitophorous Vacuole 
 
PVM Parasitophorous Vacuolar Membrane 
 
qRT-PCR Quantitative Reverse Transcriptase-Polymerase Chain Reaction                       
RNA Ribonucleic Acid 
rRNA Ribosomal Ribonucleic Acid 
 
RT-PCR Reverse Transcriptase Polymerase Chain Reaction SCID
 Severe Combined Immune Deficient 
SDS Sodium Dodecyl Sulfate 
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TAMU Texas A&M University 
 
TCA                            Tricarboxylic acid cycle 
 
UTP Uridine Triphosphate 
 
WHO World Health Organization 
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1 INTRODUCTION AND LITERATURE REVIEW 
1.1 The history of Cryptosporidium spp. 
In 1970, Cryptosporidium was first recognized by Ernest Edward Tyzzer in gastric 
glands of laboratory mice with both its asexual and sexual phases of reproduction [1]. He 
thought the oocysts excreted were spores so he identified the parasite as a sporozoan and 
name it Cryptosporidium muris. He recognized all life cycle morphological features except 
being an intracellular rather than extracellular parasite. In 1910, he suggested autoinfection 
might occur in Japanese waltzing and English mice [2]. Then, he described Cryptosporidium 
parvum as another new species that develops smaller oocysts that those of C.muris and 
infecting the small intestine of mice [3]. In 1948, the first case associated with fatality was 
in turkeys by the new species, Cryptosporidium meleagridis [4]. Yet, interest was fair for 
this parasite. Later in 1970, diarrheal cases in cattle were reported for which more interested 
was given. First 2 cases of human cryptosporidiosis were reported, a 3-years-old child and a 
39-years-old immunosuppressed patient. Both cases were in contact cattle and a dog while
presenting watery diarrhea [5]. In 1979, another case was reported by 9 -years-old child and 
52-years-old immunosuppressed patient [6]. Six out of the seven cases reported between 1976
and 1980 were immunosuppressed or immunocompromised [6]. Among the 58 cases 
reported from 1976 till 1984, 18 cases were immunocompetent [7]. Therefore, 
Cryptosporidium became a significant opportunistic human pathogen that is capable of 
infecting both immunocompromised and immnunocompetent patients. Cryptosporidial 
infections might result in severe and chronic diarrhea in immunocompromised patients, or 
mild to severe symptoms but usually self-limiting in immunocompetent individuals. 
In the 1970s, more attention was driven to this pathogen owing to the water-borne 
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outbreaks of cryptosporidiosis worldwide. An outbreak was documented in Carrollton, 
Georgia, United States of America (USA), resulting in 13,000 cases due to the contamination 
of a filtered public water supply [8]. Another outbreak has affected 5,000 cases in Wiltshire 
and Oxfordshire, UK [9]. In 1993, the most influential waterborne outbreak in Milwaukee, 
Wisconsin, USA, caused a surge in interest to the public, government and environmental 
supporters. This outbreak not only resulting in 403,000 cases with watery diarrhea and 4,400 
people were hospitalized but also associated with total costs around $96.2 million [10, 11].  
Cryptosporidium is listed as a category B priority agent in the Biodefense program by 
the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention 
(CDC) in the USA due to the moderate level of illness, ease of dissimination and level of
survellience [12]. Accordingly, subsequent studies were initiated towards the development of 
new tools for pathogen detection and understanding its biology. Recently, our knowledge of 
Cryptosporidium parasites regarding taxonomy, epidemiology, transmission, pathogenesis 
and molecular biology has enormously expanded for the ultimate goal which of preventing 
and treatment of cryptosporidiosis. A highlight in the research era is the complete genome 
sequences of C. parvum (Iowa stain) and C. hominis (isolate TU502 isolate), which revealed 
the unique biological features in this opportunistic pathogen [13, 14]. Never the less, more 
cases and outbreaks are still reported with not fully effective preventative and effective 
procedures.  
1.2 Taxonomy 
The genus of Cryptosporidium are unicellular protozoans that belong to the Phylum 
Apicomplexa, which mostly have complicated life cycles. Apicomplexans possess an apical 
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complex which contains conoid, rhoptries, micronemes, apical rings and dense granules. 
These structures are important for cell invasion and locomotion. In spite of various debates, 
Cryptosporidium is placed under the Class Coccidea as an intestinal coccidian due to the 
similarity in parasite cycle and morphology with other coccidian species [15-17]. However, 
Cryptosporidium shows significant biological differences among other coccidians, (a) It is an 
intracellular but extracytoplasmic within the host cells [18]; (b) it  has thick-walled and thin-
walled oocysts, rather than only thick-walled oocysts ; (c) the small size of oocyst and lack of 
sporocyst [2]; (d) the lack of apicoplast and its genome [19]; and (e) the insensitivity to most 
anticoccidial drugs [20]. 
More recently, the molecular and phylogentic evidences suggest a closer relationship to 
gregarines.  Recently, molecular phylogenic data shows Cryptosporidium is an early 
evolution branch at the base of the Apicomplexa, rather than as a sister to the other intestinal 
coccidia [16, 21, 22].  Moreover, it is also suggested that Cryptosporidium is more closely 
related to the to the gregarines than to the coccidia. Whether, Cryptosporidium has evoloved 
from or sister to the gregarines, it is not yet determined [23, 24]. However, Cryptosporidium 
lacks various metabolic pathways such as de novo synthesizing amino acids, pyrimidines, 
and purines which are present in the gregarines [13] [22].  
Up to date, there are 25 valid Cryptosporidium species (Table 1.1) with more than 40 
Cryptosporidium isolates referred as genotypes and requires more morphological, biological, 
and molecular data to determine whether they are valid new species [25]. Earlier, the species 
of Cryptosporidium are determined according to the host harboring the infective (oocyst) 
stage. C. muris in the mouse gastric glands and C. parvum, in the mouse intestine were the 
first 2 species discovered by Ernest Edward Tyzzer [1, 3]. Several Cryptosporidium species 
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were mistakenly named according to the host origin. C. parvum which infects wide range of 
host shows low infectivity rate in adult mouse. Therefore, the parasite discovered by Tyzzer 
in the laboratory mice and able to infect adult mouse can be the Cryptosporidium mouse 
genotype. It is the cross-transmission experiments in 1980s that validated C. parvum in which it 
can be transmitted between mice and cattle host species [18, 26]. Additionally, several newly 
named species were merged to C. parvum [27] [28, 29]. Many coccidian species were 
identified according to their distinctive oocyst morphology which can not be applied to 
Cryprosporidium because it lacks these unique features and can not be differentiated from 
each other. Also, morphological features of life cycle stages can aid in speciation but it is 
not feasible to examine each host with the unique features. More recently, genetic markers 
have opened new avenues for defining new Cryptosporidium spp. as these derived from 
genes encoding 18S ribosomal RNA (rRNA), the hyper-variable 60-kDa glycoprotein 
(gp60), and the oocyst wall protein (COWP)[25, 30].  Since one criterion was not enough to 
define Cryptosporidium spp, the combination of several criteria were needed in which the 
following needs to be fulfilled: (I) oocyst morphology; (II) genetic characterization; (III) 
demonstration of natural and, whenever feasible, experimentally defined host specificity; 
(IV) compliance with International Code of Zoological Nomenclature (ICZN) [25, 31, 32].
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Table 1 The twenty-five valid named Cryptosporidium species and their host types [33] 
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1.3 Morphology of life cycle stages 
The life cycle of Cryptosporidium spp. is complicated. It contains 6 developmental 
stages with different morphological features as shown by light and electron microscopy. The 
main site of infection of C. parvum (Human and other animals) and C. hominis (exclusive in 
human) is the small intestine. Sites may vary according to the host. For example, the ileum 
above the cecal junction is the favorable site for C. parvum in mice and calves. Infection can 
also occur in extra intestinal sites  as respiratory system, gall bladder and liver in animals 
and immunocompromised patients [34]. 
1.3.1 Oocysts 
The oocysts of Cryptosporidium spp. are round to oval in shape, with sizes ranging 
from 3.7 to 8.4 µm in length and 3.2 to 6.3 µm in width. Cryptosporidium oocyst wall is a 
trilaminar structure. The outer layer is an irregular electron-dense layer (8.5 ± 0.6 nm) while 
the middle layer is translucent (4.0 ± 0.2 nm). The inner layer is made of two electron-dense 
layers (13.0 ± 0.5 nm and 18.6 ± 1.6 nm, respectively). The thin walled oocysts lack the thin 
inner wall.  [35, 36]. The wall has a suture structure through which sporozoites are released 
during excystation [37]. Each mature oocyst contains four sporozoites, and one membrane-
enclosed residual body with large lipid body inside. The residual body has a large lipid body, 
protein inclusions and amylopectin granules [38]. The tough oocyst wall is mainly the 
reason of being resistant to common disinfection techniques for water treatment as 
chlorination [39]. 
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1.3.2 Sporozoites and merozoites 
The mature oocyst undergoes excystation under favorable conditions within the host 
to release the four infective sporozoites. Merozoites develop in a meront which upon 
maturation, merozoites are released.  Both sporozoites and the merozoites a can invade host 
cells and are morphologically similar. They are crescent in shape, with the anterior end slightly 
pointed and the posterior end rounded. In the anterior region, there is an apical complex that is 
important for locomotion and cell invasion by having apical rings, conoids, rhoptries, 
micronemes, and electron-dense granules. 
1.3.3 Trophozoites 
Trophozoites are transitional forms of sporozoites or merozoites to meronts. The crescent 
shape sporozoites or merozoites approach the anterior end of the host cells for invasion and 
become spherical to develop the trophozoite stage. Trophozoites are round or oval shaped and 
vary in size ranging (2.0 to 2.5 µm) and contains a single nucleus with a prominent 
nucleolus. At the site of electron-dense attachment to the host cells, unique feeder organelle 
is formed. Also, its apical complex starts to disappear, and vacuoles cluster to form 
parasitophorous vacuole membrane (PVM) during invasion. This membrane is formed by 
extensions from host cell cytoplasmic membrane to surround the parasite which is not in 
contact with the host cell cytoplasm. Hence, it is intracellular but extra cytoplasmic [17, 40, 
41]. 
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1.3.4 Meronts 
The trophozoites will undergo asexual phase of reproduction (merogony) to form 
multinuclear meronts. The type I meronts are first generation of meronts from which the 
merozoites are released become extracellular to re-infect new host cells. Then, they develop 
into either type I or type II meronts which are are morphological similar (4-5 µm in 
diameter), except that type I meront has 6 or 8 merozoites, while a type II meront typically 
has 4 merozoites. Type I merozoites may enter one or more cycles of mergony before 
developing into type II meronts . During maturation, merozoites become more elongated and 
develop more micronemes, rhoptries, electron dense granules and ribosomes in the 
cytoplasm [18]. 
1.3.5 Gamonts and gametes (sexual stages) 
Type II merozoites invade new host cells and undergo sexual development to form 
microgamonts (male)and microgamonts (female)[40]. A microgamont has a very compact 
nucleus and lacks rhoptries, unlike the merozoites [18](16). Mature microgamont may 
contain up to 16 bullet-shaped microgametes which are rod shaped lacking flagella and 
mitochondria, unlike other coccidia. It also has a  slightly falttened anterior end with 
condensed nucleus. A mature macrogamont contains only one macrogamete which has a 
large nucleus, prominent nucleolus and a feeder organelle [18, 36]. 
1.4 Life cycle 
The complicated life cycle of Cryptosporidium species involves both sexual and 
asexual phases within a single host. The sporulated oocyst is the infective stage that is 
excreted in the host feces [17, 40] as shown in Figure 1. 
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The infection is acquired through the ingestion of food or water containing the occysts 
by the susceptible host. Suitable conditions are required for excystation of sporozoites, such 
as appropriate stomach reducing conditions, temperature, pancreatic enzymes, and bile salts 
[42, 43]. Excystation was demonstrated in aqueous solutions in experimental conditions 
which may assist in autoinfection and extra-intestinal infections[17, 34]. Excystation of 
oocysts release the motile sporozoites through an open suture in the oocyst wall [36].The 
slender shaped motile sporozoite will rapidly attach to the apical end of the intestinal cells 
and become a spherical-shaped trophozoite. During invasion, vacuoles are formed to surround 
the parasite and form pre-parsitophorous vacuole which then fuses with the host cell membrane to 
form the paarsitophorous vacuole (PV) [36, 44, 45] [46]. Asexual reproduction, also called 
merogony, begins when the trophozoite nucleus divides to form type I meront containing 8 to 
16 haploid merozoites, first generation of merogony. The type I merozoites infect other host 
cells to enter second generation of merogony, forming type II meront containing four 
merozoites. Type II merozoites invade new host cells and initiate sexual reproduction in 
which they differentiate in to microgamonts (male) or macrogamonts (female) are formed. 
Fertilization between micro- and macro-gametes forms the diploid cells, zygotes. A zygote 
immediately undergoes sporogony to form an oocyst containing four haploid sporozoites. 
Most of the oocysts (80%) of the oocysts have a thick, two-layer wall and released into the 
environment while the remaining (20%) are thin, one layer walled. The thin walled oocysts 
can easily rupture within the same host and release sporozoites for auto-infection. Also, they 
may have role in persistent and chronic infections in immunosuppressed patients [18, 47]. 
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Figure 1 Life cycle of Cryptosporidium parvum 
(Reproduced from https://www.cdc.gov/parasites/crypto/pathogen.html) 
Sporulated oocysts, containing 4 sporozoites, are excreted by the infected host through feces 
and possibly other routes such as respiratory secretions . Transmission of Cryptosporidium 
parvum and C. hominis occurs mainly through contact with contaminated water (e.g., drinking 
or recreational water). Occasionally food sources, such as chicken salad, may serve as 
vehicles for transmission. Many outbreaks in the United States have occurred in waterparks, 
community swimming pools, and day care centers. Zoonotic and anthroponotic transmission 
of C. parvum and anthroponotic transmission of C. hominis occur through exposure to 
infected animals or exposure to water contaminated by feces of infected animals . 
Following ingestion (and possibly inhalation) by a suitable host , excystation  occurs. The 
sporozoites are released and parasitize epithelial cells ( , ) of the gastrointestinal tract or 
other tissues such as the respiratory tract. In these cells, the parasites undergo asexual 
multiplication (schizogony or merogony) ( , , ) and then sexual multiplication 
(gametogony) producing microgamonts (male)  and macrogamonts (female) . Upon 
fertilization of the macrogamonts by the microgametes ( ), oocysts ( , ) develop that 
sporulate in the infected host. Two different types of oocysts are produced, the thick-walled, 
which is commonly excreted from the host , and the thin-walled oocyst , which is 
primarily involved in autoinfection. Oocysts are infective upon excretion, thus permitting 
direct and immediate fecal-oral transmission. 
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1.5 Cryptoporidiosis 
Cryptosporidium parasites are the causative agents of cryptosporidiosis in humans 
and animals [48-50]. Cryptosporium typically infects epithelial cells in the microvillus 
border of the gastrointestinal tract of hosts causing severe watery diarrhea. C. parvum and C. 
hominis are the two major human pathogens. According to the global enteric multicenter 
study (GEMS), C. parvum and C. hominis are among the top two (or top four) diarrheal 
pathogens in children under the age of one (or age of five) in developing countries. These 
diarrheal pathogens not only impede the growth and cognitive fitness of children but are 
also associated with fatality in toddlers aged 12–23 months [51-53]. Additionally, 
Cryptosporidium can cause opportunistic infection with prolonged, life threatening diarrhea 
in AIDS patients but mostly self-limited in immunocompetent patients [48, 49]. 
1.6 Immune responses 
The host immune system is necessary to control and eliminate Cryptosporidium 
infections which rely on the host immune system. Cryptosporidiosis is usually self-limiting 
in immunocompetent individuals but can be persistent and fatal in immunocompromised 
patients as AIDS patients. There are still gaps in understanding the mechanism responses. 
Both innate and adaptive immune responses in hosts are important to controlling the disease 
but the innate immunity has the major contribution in clearing the infection [54, 55]. Here we 
will highlight the major components of the immune response to cryptosporidial infections 
in different hosts. 
1.6.1 T cells (CD4+ and CD8+ T cells)
The adaptive response is stimulated by specific antigens recognized by T-cells and 
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B-cells and amplifies the elements of the innate immune response. CD4
+ 
T-cells are
activated by the antigen presenting cells (macrophages and dendritic cells) which in turn 
stimulate the B-cells to proliferate and produce antibodies [56]. In cryptsporidial infections, 
the T cell immune response relies mainly on CD4
+ 
T-cells rather than on CD8
+ 
T cells. The
protective role of CD4
+ 
T cells is evident in several mice studies. Wild type mice were able
to eliminate the infection within 8 weeks ,unlike the MHC class II deficient mice lacking 
CD
+ 
4 cells [57] . Consistently, mice infected with C.muris  and treated with anti- CD4
+
antibodies to deplete the CD4
+ 
T cells showed exacerbated infections [58]. Also,
lymphocytes from immunocompetent mice were injected into SCID mice, thus providing 
protective effects against cryptosporidium infection until CD
+ 
4 cells were depleted. [58]
[59, 60]. The role of CD8
+ 
T cells is still debatable. MHC class I deficient mice lacking
show comparable levels of infection with wild type [57]. Added to this, SCID mice lacking 
CD8
+8
 cells could not eliminate the infection when provided with spleen cells of
immunocompetent mice [59]. On the other hand, another study showed SCID could not 
overcome the infection  when supplied with donor spleen cells [58]. Also , treatment of 
immunocompetent mice with anti- CD8
+
 had no effect on controlling the infection but the
combination of both , anti- CD8
+ 
and anti- CD4
+
antibodies exacerbates the infection [60].
Moreover, studies in human were conducted showing the dependence of the clinical 
outcome on the CD4
+ 
cell count. The CD4
+ 
cell counts over 180 cells/µl, cryptosporidiosis 
is generally self-limited in human but infection is life-threatening in patients (as AIDS 
patients) with lower CD4
+ 
cells counts (<50 cells/µl) [54, 61](72,74). Additionally, HIV-
infected patient was cleared from cryptosporidiosis by the rapid increase in CD4
+ 
cells 
during highly active antiretroviral therapy [62]. These results support the significance of 
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CD4
+ 
cells in immune response towards cryptosporidium infections with moderate role 
CD8
+
 cells.
1.6.2 B cells 
The roles of B cells and antibodies in cryptosporidiosis immune response are not yet 
clear. B cell deficient mice show comparable susceptibility to infection with the wild type 
[63]. Another study showed no change in the protective effect in SCID mice treated with spleen 
cells lacking B cells compared with mice treated with spleen cells that are not depleted of B cells 
[64]. Also, mice lacking B cells follow similar pattern of infection and clearance as the control 
mice [65].  
On the other hand, studies to understand the role of antibodies in immune response were 
contradictory. A relation between selective IgA deficiency and persistent cryptosporidial 
infection was studied supporting the role of B cells in the immune response [66]. Patients with 
congential hypogamma globulinemia fail to clear the parasite infection [5]. The high serological 
responses to a 27-kDa Cryptosporidium-antigen was accompanied with a reduced risk of 
diarrhea in both HIV-negative and HIV-positive patients [67]. Also, in immunocompetent 
patients infected with C. parvum,  the level of secretory IgA was elevated in patients excreting 
oocysts or with diarrheal symptoms [68] . Oral treatment of rodents with secretory IgA 
provided passive protection against infection [67]. On the contrary, Cryptosporidium-
specific antibody levels are probably unrelated to the diarrheal symptoms [69]. High levels of 
parasite-specific antibodies (secretory IgA) were noticed in AIDS patients with chronic 
cryptosporidiosis [70]. Experiments with B- cell deficient mice showed comparable 
susceptibility to C. parvum infection compared with the control group [63] . In a C.muris study, 
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SCID mice treated with splenic cells depleted of B-cells similar pattern of infection as the group 
not receiving depleted B-cells [64]. Therefore, B cells and antibodies may have role in 
protection against infection but may not be crucial as other factors. 
1.6.3 IFN-γ 
 IFN-γ is a Th1 cytokine that plays a significant role in the adaptive response towards 
cryptosporidial infections. Treatment of SCID and immunocompetent mice with splenic cells 
and anti-IFN-γ neutralizing antibodies enhanced the growth of the parasite [64, 71].Also, 
CD4
+ 
T-cells purified from C. parvum immunized mice could proliferate and produce IFN- γ
upon incubation with C. parvum antigen [72]. C. parvum infections were more exacerbated 
in IFN-γ knockout SCID mice than SCID mice [73](90). Also, the infection was exacerbated 
when mice were treated with both, anti- CD4
+ 
and anti-IFN-γ antibodies more significantly
than with either. This supports the relation between CD4
+ 
T-cells and IFN-γ in the
immune response to C. parvum. The early and significant increase in ileal IFN-γ content is 
associated with improved outcomes and recovery from C. parvum infection was observed 
in humans, mice and calves [74-77]. Not only, the IFN-γ mRNA and protein expression 
was induced by C. parvum [78] [74] [79] but also has a pattern similar to the pattern of 
acute infection [74]. As a therapeutic agent, IFN-γ treatment was able to diminish the 
parasite burden in immunosuppressed rat [80]. However, it did not provide a protective 
effect against the infection in immunodeficient mice [81, 82]. 
1.6.4 IL-12 
Interleukin 12 (IL-12) is a  cytokine released by the antigen presenting cells 
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(macrophages and dendritic cells) to induces NK cells and T cells to produce INF-γ in C. 
parvum infection [83]. Not only the treatment of immunocompetent mice with IL- 12 prior to 
the inoculation with C. parvum oocysts provided protection form the infection but also the 
treatment with anti-IL-12 antibodies exacerbated the infection [78]. IL-12 protection was also 
associated with IFN-γ production.  In which the IL-12 treatment increased the levels of 
intestinal IFN-γ mRNA which is also related to early control of infection [79]. Despite of the 
increase in T cells count and expression of INF-γ, the treatment with IL-12 prior to infection 
in calves did not stimulate adequate resistance [84]. C. parvum infections ,with as low as 
100oocysts ,would result in acute diseases in the IL-12 knockout adult C57BL/6 mice but 
were able to recover within 2 weeks [85] . Therefore, IL-12 knockout C57BL/6 mice is used 
as a model for testing drug efficacies against acute cryptosporidiosis. 
1.7 Treatments 
The outbreak of cryptosporidiosis Milwaukee in 1993 is the greatest water born outbreak 
documented in the history of the United States. Together with the subsequent outbreaks 
worldwide, attention was given to cryptosporidium by the public, government and 
environmental agencies [11]. New drugs are urgently needed against this pathogen for 
which various in vitro, in vivo and clinical studies were conducted. However, there is no 
fully effective drug against cryptosporidiosis up to date. Currently, nitazoxanide (NTZ) is 
the only FDA approved to treat cryptosporidiosis in immunocompetent patients, but its 
efficacy is still questionable. Here, we will briefly review the current therapeutic agents with 
anti-cryptsporidial activities. 
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1.7.1 Nitazoxanide 
Nitazoxanide is the only FDA-approved drug for treatment of cryptosporidiosis in 
immunocompetent individuals but not in immunocompromised individuals. In an earlier 
study, three days course of 500 mg of nitazoxanide for adults or 10 mg for children (1-11 
years) twice daily significantly decreased diarrhea symptoms and oocyst shedding in 
immunocompetent patients compared with placebo (114). Among AIDS patients, 
nitazoxanide was also effective against C. parvum in AIDS patients with less diarrheal 
symptoms [86]. NTZ and its metabolites, tizoxanide (TZ) and tizoxanide- glucuronide 
(TZglu) inhibited the parasite growth at less than 10 mg/ml [87, 88]. No safety issues were 
documented up to 3000mg/day or with long duration of NTZ treatment [89]. 
1.7.2 Paromomycin 
Paromomycin is an aminoglycoside with broad spectrum of antimicrobial activity, 
which is mainly used to treat Giardia and amoebic intestinal infectious. It is poorly absorbed 
from the gut epithelium with oral treatment. It acts by targeting the aminoacyl tRNA site of the 
ribosomes, thus disrupting the protein synthesis. The anti-cryptosporidial activity of 
paromomycin was reported in various studies [90-92] including its efficacy in HIV-infected 
patients [93]. Another study was showed significant parasitological cure by paromomycin 
among AIDS patients infected with cryptosporidiosis [94]. On the contrary, a study showed 
paromomycin is not more effective than placebo in an AIDS patients with cryptosporidial 
infection  [95]. Paromomycin is not approved by the FDA drug for treatment of 
cryptosporidiosis but it is used to alleviate the symptoms. In AIDS patients, it is not 
recommended to be used unless with HAART (Highly-active anti-retroviral treatment) [96]. 
17 
1.7.3 Highly-active anti-retroviral therapy 
The improvement in the immune system of HIV patients is the key for treatment of 
cryptosporidiosis. This is achieved by the highly-active anti-retroviral therapy (HAART) that 
can improve the outcome of opportunistic infections including cryptosporidiosis [96].  HAART 
can improve cryptosporidiosis symptoms with total parasitological cure in AIDS patients. It is 
also associated with increase in the CD4
+ 
T-cells which have important role in the immune
response against the parasite as mentioned earlier [97]. However, some case control studies 
reported during the initial treatments [98]. Protease inhibitors (ritonavir, saquinavir and indinavir) 
were also studied as anti-cryptosporidial agents in which they show dramatic reduction in the 
parasite loads in both, in vitro and in vivo models [99, 100].  
1.7.4 New thiazolide derivatives 
Modifications in the chemical structure of nitazoxanide were performed to synthesize 
new NTZ derivatives. Romark Center for Drug Discovery has synthesized 42 thaizolides, among 
which, 26 inhibited C. parvum growth invtro by more than 95%. Added to this, all the 
derivatives with chlorine group instead of the nitro group and most of the bromo thiazolodes 
showed more than 95 % inhibition on the parasite growth in vitro [101]. 
1.8 Energy metabolism in Cryptosporidium 
The whole genomes of C. parvum has been sequenced and broadens our knowledge about 
C. parvum metabolism. Cryptosporidium are unable to synthesize most nutrients de novo,
including amino acids, nucleotides and fatty acids Unlike other apicomplexans, C. parvum has a 
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highly streamlined metabolism and lacks many metabolic pathways such as mannitol cycle, 
shikimate pathway and electron transport chains, and also has pathways that are highly divergent 
from other apicomplexans such as the inositol monophosphate dehydrogenase (IMPDH) [13, 
14]. This explains the limited classical drug targets in C. parvum and its insensitivity towards 
many drugs that are usually effective against other apicomplexans. C. parvum lacks the genes 
encoding the Krebs cycle along with the apicoplast and mitochondrial genomes that are found in 
other apicomplexans [19]. Although C. parvum may possess a remnant mitochondrion, it lacks 
Krebs cycle and cytochrome-based respiration, thus mainly, if not only, depending on glycolysis 
for ATP production [13, 102]. Within the glycolytic pathway, C. parvum obtains glucose and 
other hexoses either directly from the host or through degradation of polysaccharides [103, 104]. 
To enter metabolic pathways, glucose needs to be activated by hexokinase (HK) to form glucose-
6-phosphate (glucose-6P) that will be further converted to fructose-6-phosphate (fructose-6P) by
glucose-6P isomerase (GPI), and then to fructose-1,6-pyrophosphate by pyrophosphate-
dependent phosphofructokinase (PPi-PFK) before being split into two triose-phosphate 
molecules.  Similar to other microaneorobic protists as Giardia and Trichomonus, C. parvum has 
pyrophosphate-dependent phosphofructokinase (PPi-PFK), thus generating 3 ATP molecules 
rather than 2 ATP molecules by human and other aerobic organisms that use the ATP dependent 
PFK [105]. Phosphoenol pyruvate (PEP) is then converted to pyruvate by pyruvate kinase (PK) 
releasing one ATP molecules or through malate dehydrogenase (MDH). Pyruvate is converted to 
acetyl-CoA by the bifunctional pyruvate:NADP+ oxidoreductase (PNO) which has pyruvate 
ferrodoxin oxidoreduactase  (PFO) domain fused with the cytochrome P450 . This is a unique 
structure in Cryptosporidium that differs from the pyruvate dehydrogenase (PDH) complex in 
other apicomplexans and in humans and animals but also found in Euglena gracillis [106] . Three 
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organic end products are produced from Acetyl-CoA which are lactate by lactic acid 
dehydrogenase (LDH), ethanol by aldehyde dehydrogenase (AdhE) and actetate by acetyl CoA 
ligase (AceCL). All apicomplexans LDH and MDH including CpLDH and CpMDH are acquired 
from α- proteobacterial ancestor [107, 108]. Besides, CpMDH and other apicomplexans have one 
cytosolic MDH unlike other eukaryptes which have several MDH isoenzymes (cytosolic, 
mitochondrial and apicoplastic) [108]. The degradation of polysaccharides give rise to glucose-
1P which can give rise to glucose-6P by glucomutase enzyme. Unlike other apicomplexans, 
Glucose-1P and UDP glucose can be used by C. parvum in the synthesis of an antistress 
molecule, trehalose. It is an anti-oxidant and protein stabilizing agent that is synthesized in some 
bacteria and plants [109, 110]. Thus, suggesting the possibility of using trehalose as a source of 
energy, however, other enzymes involved in its metabolism are not yet revealed. 
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 Figure 2 The role of CpHK and CpGPI 
in the unique glycolytic pathway and 
major connections in Cryptosporidium 
parvum [104] 
Abbreviations: ACC, acetyl-CoA 
carboxylase; AceCL, acetic acid-CoA 
ligase; ADH1, alcohol dehydrogenase 
1; adhE, type E alcohol 
dehydrogenase 
(bifunctional); GDBE, glycogen 
debranching enzyme; GGH: 
Glucoside glucohydrolase; GP: 
glycogen phosphorylase; HK, 
hexokinase; LDH, lactate 
dehydrogenase; PGI, phosphoglucose 
isomerase; PGluM, phosphoglucose 
mutase; PMI: phosphomannose 
isomerase; PDC: pyruvate 
decarboxylase; PNO, 
pyruvate:NADP+ oxidoreductase; PPi
-PFK: pyrophosphate-dependent
phosphofructokinase.
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2 EXPLORING GLUCOSE -6-PHOSHPHATE ISOMERASE (GPI) AS A 
POTENTIAL DRUG TARGET IN CRYPTOSPORIDIUM PARVUM
2.1 Overview 
Cryptosporidium parasites are the causative agents of cryptosporidiosis in humans and 
animals [49, 111, 112]. According to the global enteric multicenter study (GEMS), C. parvum 
and C. hominis are among the top two (or top four) diarrheal pathogens in children under the age 
of one (or age of five) in developing countries.  These diarrheal pathogens not only impede the 
growth of children, but are also associated with fatality in toddlers aged 12–23 months [51, 113, 
114]. Additionally, Cryptosporidium can cause opportunistic infection with prolonged, life-
threatening diarrhea in AIDS patients [49, 112]. Up to date, nitazoxanide is the only FDA-
approved drug in the United States to treat cryptosporidiosis in immunocompetent patients, while 
there are no effective and safe treatments for cryptosporidiosis in immunocompromised patients. 
Also, there is no approved treatment for cryptosporidiosis in animals in the United States [49, 
115, 116]. Therefore, there is a critical need for development of new anti-cryptosporidial drugs. 
Unlike other apicomplexans, C. parvum has a highly streamlined metabolism and lacks many 
metabolic pathways such as mannitol cycle , shikimate pathway and electron transport chains, 
and also has pathways that are highly divergent from other apicomplexans such as the inositol 
monophosphate dehydrogenase (IMPDH) [13, 117]. This explains the limited classical drug 
targets in C. parvum and its insensitivity towards many drugs that are usually effective against 
other apicomplexans. C. parvum lacks the genes encoding the Krebs cycle along with the 
 Parts of this section are reprinted from Rana Eltahan , Fengguang Guo , Haili Zhang , Lixin Xiang , Guan Zhu, 
Discovery of ebselen as an inhibitor of Cryptosporidium parvum glucose-6-phosphate isomerase (CpGPI) by high-
throughput screening of existing drugs. International Journal for Parasitology: Drugs and Drug Resistance, Volume 
8, Issue 1, April 2018. Article is Open Access and available online at: https://doi.org/10.1016/j.ijpddr.2018.01.003 
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apicoplast and mitochondrial genomes that are found in other apicomplexans [19]. Although C. 
parvum may possess a remnant mitochondrion, it lacks Krebs cycle and cytochrome-based 
respiration, thus mainly, if not only, depending on glycolysis for ATP production [13, 102]. The 
glycolytic enzymes, many of which are highly divergent from humans and animals, may 
therefore be explored as potential drug targets. 
Within the glycolytic pathway, C. parvum obtains glucose and other hexoses either 
directly from the host or through degradation of polysaccharides [103, 104]. To enter metabolic 
pathways, glucose needs to be activated by hexokinase (HK) to form glucose-6-phosphate 
(glucose-6P) that will be further converted to fructose-6-phosphate (fructose-6P) by glucose-6P 
isomerase (GPI), and then to fructose-1,6-pyrophosphate by pyrophosphate-dependent 
phosphofructokinase (PPi-PFK) before being split into two triose-phosphate molecules (Fig. 
1A).  
          In the present study, we characterized the molecular and biochemical features of the GPI in 
C. parvum (CpGPI) encoded by a single-copy CpGPI gene. We also screened a Prestwick 
chemical library containing 1200 known drugs for potential anti-CpGPI activities and discovered 
that ebselen could inhibit CpGPI. We observed that ebselen inhibited the activity of CpGPI more 
effectively than that of human (Homo sapience) GPI (HsGPI), and that the growth of C. parvum 
in vitro could be inhibited by ebselen at levels nontoxic to the host cells. 
2.2 Materials and methods 
 
2.2.1 Molecular cloning of CpGPI gene and expressionof recombinant CpGPI protein 
 
The oocysts of C. parvum (Iowa-1 strain) were purchased from Bunch Grass Farm (Deary, 
ID) and experiments used oocysts that were less than three months old since harvest. Oocysts 
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were purified from calf feces by a sucrose-gradient centrifugation, followed by treatment with 
10% Clorox on ice for 7 minutes and then washed 5 – 8 times in pure water  [118]. Oocysts were 
further purified by a Percoll gradient centrifugation protocol and finally suspended in phosphate-
buffered saline (PBS; pH7.2) and stored at 4°C before use. 
CpGPI gene has been annotated by the C. parvum genome-sequencing project (Gene ID: 
cgd2_3200; GenBank: XP_626511). The open reading frame (ORF) was amplified from the C. 
parvum genomic isolated from oocysts with a DNeasy Blood & Tissue Kit (Qiagen) by PCR 
using a high-fidelity Pfu DNA polymerase with the primer pair of CpGPI-F-BamHI (5′ AGG 
GAT CCA TGC CAG AAC TTT ATG AAC 3′) and CpGPI-R-SalI (5′ ATG TCG ACA TTC 
GTC AGG CTC TTT GAA 3′). The amplicons were ligated into a pCR2.1-TOPO vector 
(Invitrogen) linearized by BamI and SalI, followed by transfection into NEB 5-alpha Escherichia 
coli cells (New England BioLabs). Plasmids were isolated from several bacterial colonies using 
an E.Z.N.A. Plasmid Mini Kit I (Omega Bio-tek; Norcross, GA), and sequenced to confirm their 
identities and sequence accuracy. The DNA fragment containing the CpGPI ORF was then 
subcloned into a pMAL-c2E-TEV-His plasmid derived from the pMAL-c2E plasmid, which was 
engineered to encode a tobacco etch virus (TEV) cleavage site between the N-terminal MBP-tag 
and C-terminal fusion protein, together with a His-tag at the C-terminus of recombinant protein 
[119]. The expression of CpGPI as an MBP-fusion protein (MBP-CpGPI) was carried out in the 
Rosetta-2 strain of E. coli competent cells (EMD Millipore; Burlington, MA). The induction of 
expression and the purification of MBP-fusion proteins using amylose resin-based affinity 
chromatography followed standard procedures [119]. The quality and the quantity of 
recombinant MBP-CpGPI protein were evaluated by SDS-PAGE and Bradford protein assays 
using bovine serum albumin (BSA) as a standard. 
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2.2.2 Biochemical assays and high-throughput screening of known drugs 
 
All chemicals were purchased from Sigma-Aldrich (St. Louis, MO) or as specified. The 
glucose-6P dehydrogenase (G6PDH)-coupled assay was used to evaluate the CpGPI enzyme 
activity and kinetics by a reverse reaction that converted fructose-6P into glucose-6P by CpGPI 
and then converted glucose-6P into glucono-1,5-lactone-6-phosphate by G6PDH using NAD+ as 
a cofactor (Fig. 1A). A typical assay was performed using 200 μL reactions containing D-
fructose-6P (2 mM), NAD+ (0.2 mM), G6PDH (2 U), MgCl2 (5 mM) in Tris.HCl buffer (50 mM, 
pH8.5), and MBP-CpGPI or MBP (50 ng). The reaction started with the addition of MBP-CpGPI 
(or MBP). The production of NADH was monitored spectrophotometrically at 340 nm every min 
for up to 30 min in a Multiscan Spectrum spectrophotometer (Thermo Scientific; Waltham, MA). 
MBP-tag only was used in all assays as negative control and for background subtraction. 
The G6PDH-coupled assay was employed to screen the Prestwick chemical library 
containing 1,200 known drugs (http://prestwickchemical.com) to identify potential anti-CpGPI 
activities. Each reaction in the primary screening was performed at least twice independently in 
the presence of 20 μM compounds at room temperature. Each 96-well plate contained two 
triplicated negative controls including standard reactions without CpGPI, but containing MBP-
tag, and reactions containing CpGPI and diluent (1.0% DMSO), and a positive control using 
erythrose-4 phosphate (erythrose-4P) at 0.2 mM. 
After ebselen was identified as the greatest inhibitor, another assay was performed to confirm 
that the effect observed in the CpGPI/G6PDH-coupled assay was attributed to the inhibition of 
ebselen on CpGPI, rather than to that of G6PDH. This assay used glucose-6P as the substrate in 
the absence of CpGPI and F6P. Lowered levels of G6PDH (0.04 U) and glucose-6P (0.2 mM)  
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were used to minimize the potential masking of the inhibitory effect on G6PDH. A more detailed 
analysis was performed to determine the IC50 value of ebselen on CpGPI. MBP-tag only was 
used in all assays as a negative control and for background subtraction. The effect of ebselen on 
the enzyme activity of human GPI (HsGPI) (purchased from Biovision; Milpitas, CA) was 
similarly carried out for comparison. All assays were performed at least twice in triplicated 
reactions at room temperature (23 °C). Enzyme kinetic data were analyzed using GraphPad 
Prism v5.0f (http://www.graphpad.com) with appropriate models.  
The reversibility of the inhibition of ebselen on CpGPI was tested by an inhibitor dilution 
assay.  100 μM of ebselen was pre-incubated with 100 ng of CpGPI in a volume of 4.0 μL on ice 
for 10 min, followed by the addition of other reaction components to reach a final concentration 
of ebselen at 2 μM in a 200 μL reaction (i.e., 50-fold dilution of ebselen). Whether the reducing 
agent dithiothreitol (DTT) could block the inhibition of ebselen on CpGPI was evaluated by pre-
incubating DTT with CpGPI in a volume of 3.0 μL on ice for 10 min prior to the addition of 
other reaction components (including ebselen). Whether DTT could reverse the drug inhibition 
was evaluated by pre-incubating CpGPI with ebselen on ice for 10 min prior to the addition of 
other reaction components (including DTT). In the two DTT assays, the final reaction volume 
was 200 μL containing CpGPI (100 ng), ebselen (100 μM), and DTT (100 mM). Reactions 
containing DTT without pre-incubation were included in both assays as a control. 
2.2.3 Drug efficacy against the parasite growth in vitro 
 
A quantitative real-time RT-PCR (qRT-PCR) assay developed in our laboratory was used to 
evaluate drug efficacy against the growth of C. parvum in vitro [87, 120]. Briefly, HCT-8 cells 
(ATCC # CCL-225) were seeded in 96-well plates in RPMI-1640 medium containing 10% fetal 
bovine serum (FBS), and cultured at 37 °C under 5% CO2 atmosphere overnight or until they 
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reached to between 80% – 90 % confluence. Fresh C. parvum oocysts were purified as described 
[87, 120], and were added to the host cell monolayers with a parasite to host cell ratio at 1:2 (i.e., 
2×104 oocysts with ∼4×104 host cells per well). After incubation for 3 h at 37 °C, during which 
time the parasites underwent excystation, the medium was exchanged to remove the free 
parasites. Infected cells were incubated for an additional 41 h (total 44 h infection time) with 
ebselen at specified concentrations. 
The microplates were centrifuged at 1,000 × g for 10 min in a plate centrifuge (Heraeus 
Megafuge 16; Thermo Scientific, Waltham, MA) to ensure that all cells, including 
merozoites,that could be released into the medium were firmly attached at the bottom of the 
wells. Cells were gently washed at least 3 times with 200 μL PBS, followed by the addition of 
150 μL/well of ice cold iScript RT-qPCR sample preparation reagent (Bio-Rad Laboratories; 
Hercules, CA). The plates were then sealed with adhesive sealing films and placed in a bucket 
containing ice to be vortexed for 20 min in a VX-2500 orbit shaker (VWR International; Radnor, 
PA), followed by incubation at 75 °C for 15 min, and finally centrifuged (5 min, 2,000 x g) to 
separate supernatants from cell debris. The supernatants were used immediately for qRT-PCR or 
stored at -80 °C for future use.  
A qScript One-Step SYBR Green qRT-PCR kit (Quanta biosciences; Gaithersburg, MD) was 
used to detect the relative levels of parasite 18S rRNA (Cp18S) and human 18S rRNA (Hs18S). 
The relative parasite loads were determined by first calculating the ΔCT values between the 
Cp18S and Hs18S in individual samples and then ΔΔCT between experimental samples and 
controls as described [87, 120-122]. The IC50 values of inhibitors were analyzed using GraphPad 
Prism version 5.0 (http://www.graphpad.com). Paromomycin (100 μg/mL) and diluent (0.5% 
DMSO) were used as positive and negative controls, respectively. Cytotoxicity of inhibitors on 
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host cells was monitored by microscopic observation of the cell morphology and detachment, 
and evaluated by an MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay 
and by detecting the relative levels of 18S rRNA in uninfected HCT-8 cells. 
 
2.3 Data analysis 
 
All the biochemical assays and in vitro drug assays were performed at least twice and 
independently. Data was analyzed with Microsoft Excel and GraphPad Prism version 5.0f or 
higher (http://www.graphpad.com). 
 
2.4 Results 
 
 
2.4.1 CpGPI enzyme kinetics 
 
CpGPI is a single copy gene with ORF defined by 1,704 nt that can be conceptually 
translated into 568 aa with an estimated molecular weight of 63.2 kDa and a pI of 8.77. CpGPI 
protein was successfully expressed as an MBP-fusion protein and purified into homogeneity for 
evaluating enzyme activity by a GPI/G6PDH-coupled assay (Figure 3A, Figure 3B). The CpGPI 
enzyme activity was pH-dependent with an optimal value at pH8.5 (Figure 3C).  CpGPI 
displayed Michaelis-Menten kinetics towards fructose-6P (Km = 0.309 mM, Vmax = 31.72 
nmol/μg/min) (Fig. 3D).  
2.4.2 Identification of ebselen as a CpGPI inhibitor from 1,200 existing drugs 
 
GPI/G6PDH-coupled assay was used to screen the Prestwick Chemical Library containing 
1,200 known drugs for identifying potential CpGPI inhibitors. Erythrose-4-phosphate (erythrose-
4P) at 200 μM was used as a positive control. Erythrose-4P was previously reported as a 
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competitive inhibitor of GPIs from other protozoa (e.g., Trypanosoma cruzi and 
 
Figure 3 Enzyme kinetic features of CpGPI 
 
Dictyostelium discoideum) [123, 124], archea (e.g., Pyrobaculum aerophilum, Methanococcus 
jannaschii, Aeropyrumpernix and Thermoplasma acidophilum) [125-127], and some other 
A) Illustrations of the reaction catalyzed by GPI and the G6PDH-coupled assay for detecting 
the CpGPI enzyme activity; B) SDS-PAGE gel image showing the expression and 
purification of recombinant CpGPI as an MBP-fusion protein. Lane M, protein markers; 
Lanes 1 and 2, total proteins from transformed bacteria before the induction of expression by 
isopropyl β-D-1-thiogalactopyranoside (IPTG); Lane 3, recombinant MBP-CpGPI protein 
purified by amylose resin-based affinity chromatography; C) Effect of pH on the activity of 
CpGPI; and D) Michaelis-Menten kinetics of recombinant CpGPI towards fructose-6P. Each 
dataset shown here represents one of the typical experiments performed independently at 
least three times. Bars represent standard errors of the mean (SEMs) derived from at least 
three replicated reactions. 
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species such as plants (e.g., spinach leaf) and fungi (e.g.,  Aspergillus Niger) [128, 129]. In this 
study, we also observed that erythrose-4P was able to inhibit CpGPI (IC50 = 131.5 μM) (Fig. 
4B). 
In the primary screening (20 μM), three compounds (i.e., ebselen, lueolin and merbromin) 
displayed ≥50% inhibition on the CpGPI enzyme activity (Fig. 4A). Merbromin, a toxic 
organomercuric compound, was excluded from further analysis. Subsequent validation 
experiments revealed that lueolin was a false-positive because it inhibited G6PDH enzyme 
activity (i.e., 53.2% and 42.7% inhibition on CpGPI and G6PDH at 20 μM, respectively), but 
confirmed ebselen as an authentic anti-CpGPI (i.e., 77.1% and 3.7% inhibition on CpGPI and 
G6PDH at 20 μM, respectively) (Fig. 4C). Ebselen (Fig. 4A, inset) was the single CpGPI 
inhibitor identified from the 1,200 existing drugs tested. 
 
2.4.3 Ebselen acted as an allosteric noncompetitive inhibitor on CpGPI 
 
Ebselen had an IC50 value of 8.33 μM on CpGPI (Fig. 5A). The value was more than 15-fold 
lower than that of the erythrose-4P. However, 100% inhibition of the CpGPI activity was not 
achieved by ebselen at concentrations up to 128 μM. The action of ebselen on CpGPI fit with a 
mixed noncompetitive model of inhibition with cooperativity (Fig. 5B). The model used in the 
nonlinear regression was derived from the equation 3.3 as described by Copeland, but modified 
with the consideration of Hill coefficient (n) [130] 
𝑣 =  
𝑉𝑚𝑎𝑥[𝑆]
𝑛
[𝑆]𝑛(1+
[𝐼]
α𝐾𝑖
)+𝐾𝑚(1+
[𝐼]
𝐾𝑖
) 
      (1) 
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Figure 4 Identification of ebselen as an inhibitor of CpGPI from existing drugs. 
 
 
 
A) Screening of the Prestwick chemical library containing 1,200 existing drugs at 20 μM 
(open round circles). Erythrose-4P at 200 μM was used as a positive control (open triangles). 
The three top hits are labeled by names, including the chemical structure for ebselen. B) 
Dose-dependent inhibition of CpGPI activity by the positive control erythrose-4P. C) Hit 
validation assay showing that ebselen was an authentic hit because it was ineffective on 
G6PDH used in the CpGPI/G6PDH-coupled assay, whereas luteolin was a false hit because 
its inhibition observed in the CpGPI/G6PDH-coupled assay was mainly attributed by 
inhibition on G6PDH. Bars represent standard errors of the mean (SEMs) derived from at 
least three replicated reactions. 
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where v is the enzyme velocity, [S] is the substrate concentration, Ki is the inhibitory constant, 
and α defined as the mode of action. In this study, the Ki value was determined to be 36.33 μM 
(Fig. 5B). The α parameter was determined to be 0.358 (Fig. 5B), indicating that ebselen bound 
to CpGPI with greater affinity then to the enzyme-substrate complex. The n values ranged from 
1.065 in the absence of an inhibitor (no cooperativity in enzyme kinetics) to 0.346 and 0.295 in 
the presence of 1 μM and 5 μM of an inhibitor (negative cooperativity), suggesting that ebselen 
acted as an allosteric noncompetitive inhibitor of CpGPI. 
 
2.4.4 Ebselen was a selective and irreversible CpGPI inhibitor 
 
Ebselen was a highly selective inhibitor on CpGPI in comparison to the human counterpart, 
as it was ineffective on HsGPI at concentrations up to 400 μM (vs. IC50 = 8.33 μM on CpGPI) 
(Fig. 5C). This inhibitor acted on CpGPI irreversibly, as the inhibition could not be reversed by 
up to 50-fold dilution of the inhibitor (i.e., from 100 μM to 2 μM) (Fig. 5D). Dilution was 
achieved by pre-incubation of enzyme and inhibitor prior to the addition of other assay 
components. 
A previous study showed that the incorporation of the reducing agent DTT could reverse the 
ebselen inhibition of human indoleamine-pyrrole 2,3-dioxygenase (IDO) [131]. In this study, 
DTT could block but not reverse the inhibition of ebselen on CpGPI, as DTT at 100 mM only 
slightly affected the inhibition when it was incubated with the enzyme prior to or during the 
reaction (Fig. 5D). These observations suggest that, similar to the properties observed for a 
Trypanosoma brucei hexokinase (TbHK1) [132], ebselen might bind to CpGPI covalently (in the 
absence of a reducing agent), likely via the modification of one or more Cys residues of CpGPI 
that was resistant to DTT treatment, while the direct interaction of DTT and ebselen could 
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interfere with the association of the inhibitor with the enzyme. 
 
2.4.5 Ebselen inhibited C. parvum growth at levels nontoxic to host cells in vitro 
 
Using a qRT-PCR-based drug testing assay, it was observed that ebselen was able to inhibit 
the growth of C. parvum in vitro at micromolar levels (EC50 = 165 μM) (Fig. 6A). Microscopic 
examination of cell morphology revealed little or no apparent cytotoxicity at the tested 
concentrations. Cytotoxicity assays by the MTT assay showed cytotoxic EC50 values for HCT-8 
cells at 700 μM, giving a safety interval (i.e., EC50[host cell]/EC50[parasite]) of 4.2 (Fig. 6B).  
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Figure 5 Inhibition of ebselen on CpGPI. 
 
A) Dose-dependent inhibition of ebselen on CpGPI enzyme activity for determining the IC50 
value; B) Allosteric kinetics of CpGPI in the presence of ebselen that fit into a mixed 
noncompetitive inhibition model; C) Effect of ebselen on human GPI (HsGPI) enzyme 
activity. The assay was performed with ebselen at concentrations up to 400 μM when it 
reached approximately maximal solubility in the assay; and D) Effects of DTT and inhibitor 
dilution on the inhibition of ebselen (Ebs) on CpGPI. In the DTT assay, pre-incubation of 
DTT and CpGPI only slightly affected the enzyme activity (lane 2), but blocked the 
inhibition of ebselen on CpGPI (lane 3). In the inhibitor dilution assay, pre-incubation of 
ebselen (100 μM) with CpGPI on ice for 10 min followed by 50-fold dilution with the 
addition of other reaction components had no effect on the inhibition of ebselen on CpGPI 
with or without DTT (lanes 4-5). Here the final concentration of ebselen in the reactions was 
2 μM that would only achieve 23.3% inhibition in a standard assay (as shown in panel A), 
rather than the 97.7% - 100% inhibition as shown in lanes 4-5. Bars represent standard errors 
of the mean (SEMs) derived from at least three replicated reactions. 
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Figure 6 Efficacy of ebselen against C. parvum in vitro. 
 
 
2.5 Discussion 
 
Cryptosporidium parasites rely on glycolysis to produce ATP as they lack the Krebs cycle 
(intestinal Cryptosporidium species only) and cytochrome-based respiration (both intestinal and 
gastric Cryptosporidium species). GPI is the second essential enzyme in the glucose glycolysis, 
catalyzing the reversible isomerization of D-glucose-6P to D-fructose-6P. GPI was previously 
studied as a potential drug target in other protozoan parasites, including apicomplexans (e.g., 
Eimeria tenella and Toxoplasma gondii) and kinetoplastid T. brucei [133-135]. More recently, 
three inhibitors (i.e., suramin, agaricic acid, and 5-phosphoarabinonhydroxamic acid) were 
identified that more selectively inhibited T. brucei GPI than the mammalian GPIs [136]. 
Determining the biochemical properties of CpGPI would increase our knowledge of the 
A) Inhibition of ebselen on the growth of C. parvum (Cp) cultured in vitro for 44 h as 
determined by a qRT-PCR assay; and B) Cytotoxicity of ebselen when incubated with the 
uninfected HCT-8 cells for 44 h at specified concentrations and determined by MTT assay. 
Bars represent standard errors of the mean (SEMs) derived from at least three replicated 
reactions. 
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glycolytic pathway in C. parvum, and also provide the basis for potentially exploring this 
enzyme as a new drug target in the parasite. 
In the present study, 1,200 existing drugs were screened in the first attempt to identify new 
CpGPI inhibitors.  It was discovered that ebselen could irreversibly inhibit CpGPI (IC50 = 8.33 
μM), but not HsGPI (at concentrations up to 400 μM). It was also found that ebselen could 
inhibit the growth of C. parvum in vitro (EC50 = 165 μM), albeit at a relatively low in vitro safety 
interval of 4.2 (Fig. 4B).  
Ebselen (2-phenyl-1,2-benzisoselenazol-3(2H)-one; CAS # 60940-34-3) is a synthetic 
organoselenium drug with anti-oxidant, anti-inflammatory, anti-atherosclerotic, anti-thrombotic, 
neuroprotective and cytoprotective properties [137-141] (Fig. 2A, inset). It has been studied for 
the treatment of various diseases including arthritis, stroke and atherosclerosis in diabetic 
patients [139, 142, 143]. This drug also displayed a number of beneficial effects in experimental 
animal models [144, 145], albeit with certain levels of cellular toxicity (e.g., induction of DNA 
damage, apoptosis and necrotic cell death).  
The toxicological effects of ebselen have not been thoroughly studied. Based on the Registry 
of Toxic Effects of Chemical Substances (RTECS) data, the lowest oral dose resulting in a toxic 
effect (TDLO) in mice and rats was estimated at 5 and 10 mg/kg, respectively, and the oral LD50 
in mice was determined at 6,810 mg/kg. In humans, a number of therapeutic doses have been 
reported. For example, ebselen was safe at an oral dose of 600 mg twice daily (eq. ~20 mg/kg for 
a 60-kg adult) for 4 days, a single dose up to 1,600 mg (~26.7 mg/kg), or 150 mg twice daily (~5 
mg/kg) for two weeks [146-148]. Although it is questionable as to whether ebselen could be 
explored for treating cryptosporidiosis, this study has nonetheless expanded the drug profile of 
ebselen by discovering its selective anti-CpGPI activity. 
36 
 
 
Ebselen is known to target several different enzymes, including those from some protozoan 
parasites (e.g., hexokinase in Trypanosoma brucei and Plasmodium falciparum), mainly by 
chemical modification of the protein SH-groups forming a stable selenosulphide complex [131, 
132, 149-154]. Therefore, it is likely that the in vitro anti-cryptosporidial efficacy of ebselen 
might be attributed to its effects on both CpGPI and other parasite enzymes. Additionally, the 
safety margin of ebselen observed in this study is small (i.e., in vitro safety interval of 4.2). 
Although ebselen is useful in studying the inhibition of CpGPI enzyme activity, further proof is 
needed to chemically and/or genetically validate CpGPI as a drug target. 
Collectively, the discovery that ebselen is a selective CpGPI inhibitor provides an 
opportunity to study the properties of the CpGPI enzyme and its enzyme-inhibitor interactions. 
This study also provides a basis for the further screening of large compound libraries to identify 
CpGPI inhibitors for potential development as anti-cryptosporidial therapeutics. CpGPI is a 
“plant-like” enzyme highly divergent from those in mammals [13]. There is a good opportunity 
to identify more selective and more potent CpGPI inhibitors for humans and other mammals with 
greater safety intervals. 
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3 ACTION OF 2-DEOXY-D-GLUCOSE ON CRYPTOSPORIDIUM PARVUM AND 
DISCOVERY OF ACTIVITIES AGAINST THE PARASITE HEXOKINASE FROM 
EXISTING DRUGS 
3.1 Overview 
 Human cryptosporidiosis is mainly caused by the infection of Cryptosporidium parvum 
(zoonotic) and C. hominis (virtually human-specific), causing water-borne outbreaks. It is one of 
the top 4 diarrheal pathogens in children in developing countries. Its infection is severe or life 
threatening in immunocompromised individuals. However, the treatment options are limited with 
only, yet not fully effective, nitazoxanide (NTZ) the FDA-approved drug for use in 
immunocompetent individuals. Enzymes in the parasite glycolytic pathway are high potential 
drug targets since this opportunistic pathogen lacks the Krebs (TCA) cycle and cytochrome 
based-respiration, so it relies mainly, if not only, on glycolysis to produce ATP. Our previous 
study revealed 2-deoxy-D-glucose can inhibit the C. parvum hexokinase, one of key enzyme in 
glycolytic pathway, and C. parvum growth in vitro, but the action and fate of 2DG in C. parvum 
was not fully investigated. This study demonstrated that the anti-cryptosporidial activity of 2DG 
was mainly attributed to the action of 2DG on CpHK, rather than the action of 2DG6P on 
CpGPI. We also performed a high-throughput screening of 1200 existing drugs using 
spectrophotometry-based assays for potential CpHK inhibitors. Four drugs (Hexachlorphene, 
thimerosal, alexidine dihydrochloride and ebselen) are identified as CpHK inhibitors with anti-
cryptospordial activities at micromolar levels (EC50: 0.53, 1.77, 8.1 and 165 μM respectively) at 
concentrations nontoxic to the host cells. The four hits have provided us new anti-CpHK 
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reagents with diversified chemical structures. Our data on 2DG action supports CpHK can serve 
as drug target and the four existing drugs can serve as new reagents for studying the enzyme 
properties. 
Cryptosporidium parvum is zoonotic protozoan parasite causing mild to severe watery 
diarrhea in humans and some other mammals [49]. Cryptosporidial infection can be prolonged 
and deadly in immunocompromised patients. It is also one of the four pathogens responsible for 
the most cases of moderate to severe diarrhea (0 – 5 years old) and increased risk of death in 
children (1 – 2 years old) in low-income countries in sub-Saharan Africa and south Asia [51, 
155]. However, fully effective drugs are yet unavailable to treat cryptosporidiosis in humans and 
animals. In fact, nitazoxanide (NTZ) is the only drug approved by Food and Drug Administration 
(FDA) in the United States to treat cryptosporidial infection in human patients with a healthy 
immune system [49, 116, 156, 157].  
Unlike other apicomplexans, Cryptosporidium has a compact genome that encodes a highly 
streamlined metabolism. In energy metabolism, C. parvum lacks Krebs cycle and cytochrome-
based respiration, but relies on glycolysis to synthesize ATP [13, 102, 158]. Its glycolytic 
pathway may start with a number of mono-, di-, and poly-saccharides (e.g., glucose, mannose, 
sucrose, amylose and amylopectin), and exits with lactate, ethanol or acetate as the organic end 
products or provides substrates for the synthesis of trehalose and N-glycans, the elongation of 
very long chain fatty acids, and the formation of complex lipids. Several unique glycolytic and 
fermentative enzymes are present in Cryptosporidium, such as the hexokinase (HK) more closely 
related to those from prokaryotes than to those from fungi, animals and plants, two 
pyrophosphate-dependent phosphofructokinases (PPi-PFKs) that differ from the ATP-dependent 
PFK in humans and animals, a bifunctional pyruvate:NADP+ oxidoreductase (PNO), and a 
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bacterial-type lactate dehydrogenase (LDH) [103, 106]. Therefore, the glycolytic and 
fermentative enzymes are an attractive subject of research not only for the understanding of the 
parasite metabolism and evolution, but also for the exploration as novel drug targets in the 
parasite. 
Cryptosporidium possesses a single hexokinase [EC: 2.7.1.1] that catalyzes the first 
committed reaction in the glycolysis of glucose and other hexoses that may be obtained from the 
host through sugar transporters or by the degradation of amylopectin. We have previously 
characterized the C. parvum hexokinase (CpHK) that showed a number of unique molecular and 
biochemical features [104]. We also observed that 2-deoxy-D-glucose (2DG), a glucose analog 
and classic HK inhibitor, was able to inhibit both the enzyme activity of CpHK and the growth of 
C. parvum in vitro. The inhibition of the parasite growth was more effective in the absence or 
lower concentrations of glucose and could rescued by adding higher levels of glucose, 
confirming that “C. parvum relies heavily on glucose as a carbon source and 2DG likely acted on 
the glycolytic pathway in the parasite”[104].  
However, the action and fate of 2DG in C. parvum was not fully investigated. It is known 
that 2DG can be phosphorylated by human and animal HK to form 2DG-6-phosphate (2DG6P) 
that cannot be further metabolized. However, it was unclear whether 2DG could also be 
phosphorylated by CpHK. The anti-cryptosporidial activity of 2DG could be attributed mostly to 
the action of 2DG on CpHK, but the action of 2DG on the parasite glucose-6P isomerase 
(CpGPI) catalyzing the second reaction and/or the action of 2DG6P on CpHK or CpGPI might 
potentially contribute to the observed anti-parasitic activity as well (Figure 11).  
The present study aimed to address the questions by determining the inhibitory effects of 
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2DG and 2DG6P on CpHK and CpGPI, and comparing the anti-cryptosporidial activity and 
cytotoxicity between 2DG and 2DG6P, which would help us to better understand the action of 
2DG in the parasite. Additionally, although 2DG can be employed to probe the effects of 
inhibition of HK, the chance for being developed into anti-cryptosporidial drug is low due to the 
little selectivity between CpHK and host HKs and its micromolar level of in vitro anti-
cryptosporidial activity (i.e., EC50 = 0.54 mM) [104]. Therefore, we also initiated a drug 
screening campaign aimed to discover more selective and more efficacious anti-CpHK 
inhibitors. As a first step of the campaign, we screened 1200 existing drugs for potential anti-
CpHK activities, and identified 4 existing drugs with not only lower micromolar level anti-
CpHK enzyme, but also lower micromolar anti-cryptosporidial growth activities as described 
below. While the screening of larger compound libraries is ongoing for discovering more 
selective and efficacious anti-CpHK inhibitors, the identification of the four hits from existing 
drugs has provided us new anti-CpHK reagents with diversified chemical structures. 
 
3.2 Materials and methods 
 
3.2.1 Chemicals and other reagents 
 
Chemicals including substrates and inhibitors at analytical grade or higher purity were 
purchased from Sigma-Aldrich (St. Louis, MO) or as specified. The compound library 
containing 1200 existing drugs was purchased from Prestwick Chemical (San Diego, CA) 
(http://prestwickchemical.com). Molecular kits and reagents were purchased from various 
resources as specified.  
Oocysts of C. parvum (Iowa-1 strain) were purchased from Brunch Grass Farm (Deary, ID) 
and only those less than 3 months old were used in the in vitro drug efficacy assay. Oocysts were 
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cleaned by a treatment of 10% Clorox in water for 10 min on ice, followed by extensive washes 
to completely remove the chlorine and suspension in PBS that were used immediately or stored 
at 4 °C before use. 
 
3.2.2 Preparation of recombinant proteins 
 
The CpHK gene (gene ID: cgd6_3800; GenBank: XM_627719) was previously cloned into 
an MBPHT-mCherry2 vector for the expression of CpHK as a recombinant protein fused with 
maltose-binding protein (MBP)-His-mCherry tags (Yu et al. 2014). The CpGPI gene (Gene ID: 
cgd2_3200; GenBank: XP_626511) was previously cloned into an pMAL-c2E-TEV-His vector 
for the expression of CpGPI as an MBP-fusion protein (Eltahan et al. 2018). The expression of 
recombinant CpHK and CpGPI proteins in Escherichia coli and the amylose resin-based affinity 
purification of recombinant proteins followed standard protocols as described (Guo and Zhu 
2012). 
For determining the selectivity of inhibitors, we also expressed the human (Homo sapiens) 
HK I (HsHK1) as an MBP-fusion protein. HsHK1 was selected from the four HKs presented in 
mammals because it is the house-keeping enzyme found in all mammalian tissues. For cloning, a 
plasmid containing the cDNA of the open reading frame (ORF) of HsHK1 gene (GenBank: 
NM_000188.2) was purchased from GeneCopoeia (Rockville, MD). The plasmid was used as a 
template for amplifying the 2754-bp HsHK1 ORF by a high-fidelity PCR using a HiFi PCR Kit 
(KAPA Biosystems, Wilmington, Massachusetts) and subcloned into pMAL-c2E-TEV-His 
vector at the EcoRI and HindIII restriction sites using NEB assembly kits (New England 
BioLabs Inc.). Primers used for HsHK assembly are HsHK_assemlby_F (att ttc agg gca tgg tac 
cgA TGA TCG CCG CGC AGC TC′) and HsHK_assembly_R (tgg tgg tga tga tgg tgg tgg tgG 
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CTG CTT GCC TCT GTG C). Clones were screened by PCR for the presence of inserts in 
plasmids, and a selected number of plasmids containing correctly oriented HsHK1 inserts were 
sequenced to confirm the accuracy of the inserts. The expression of recombinant MBP-HsHK1 
protein was carried out in a Rosetta 2 strain of E. coli cells. The induction of expression and 
purification of MBP-HsHK1 protein followed standard protocols (Guo and Zhu 2012, Eltahan et 
al. 2018, Yu et al. 2014). 
The MBP-tag was similarly expressed and purified from the blank pMAL-c2E-TEV-His 
plasmid for use as a negative control in biochemical analysis of recombinant proteins. The 
quality and quantity of MBP-tag and recombinant proteins including MBP-CpHK, CpGPI and 
MBP-HsHK1 were evaluated by SDS-PAGE analysis and Bradford protein assay using bovine 
serum albumin (BSA) as the standard.  
3.2.3 Biochemical analysis 
HK assays. The CpHK and HsHK1 enzyme activities were evaluated by two assays as 
previously described (Yu et al. 2014). The first one was an HK/glucose-6-phosphate 
dehydrogenase (G6PDH)-coupled assay that detected the product glucose-6P. Briefly, the assay 
was performed in 200 μL reactions containing D-glucose (2 mM or as specified), ATP (2.5 mM 
or as specified), NAD+ (0.3 mM), G6PDH (2 U), MgCl2 (5 mM) in Tris.HCl buffer (50 mM, pH 
7.5), and MBP-CpHK or HsHK1 (500 ng) in the absence or the presence of an inhibitor at 
specified concentrations. In this assay, glucose was phosphorylated to form glucose-6P by HK, 
and then glucose-6P was converted into glucono-1′5-lactone-6P by G6PDH. The consumption of 
NAD+ was monitored spectrophotometrically at a 340 nm every minute for up to 30 min using 
Multiscan Spectrum spectrophotometer (Thermo Scientific, Waltham, MA).  
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When an inhibitor was tested by the HK/G6PDH-coupled assay, the observed inhibitory effect 
might possibly be attributed to the action of the inhibitor on G6PDH. This possibility was tested 
by G6PDH assay, which was performed similarly to the G6PDH-coupled assay in the absence of 
HK and glucose, but using glucose-6P (0.2 mM) as the substrate. A lower concentration of 
G6PDH (0.04 U) was also used to avoid the potential masking of the inhibitory effect on G6PDH 
(Yu et al. 2014).  
The second one was a pyruvate kinase/lactate dehydrogenase (PK/LDH)-coupled assay. This 
assay detected the formation of ADP, thus allowing the evaluation of HK activity towards 
various substrates in addition to glucose, such 2DG in this study. It was performed in 200 μL 
reactions containing D-glucose (5 mM) or other substrates (e.g., 2DG) at specified 
concentrations, ATP (2.5 mM), phosphoenolpyruvate (PEP; 1 mM), NADH (0.15 mM), PK (5 
U), rabbit muscle LDH (10 U), and MBP-CpHK, MBP-HsHK1 or MBP (500 ng). In this assay, 
ADP was converted back to ATP to produce pyruvate from PEP by PK. Pyruvate was then 
converted to lactate and the consumption of NADH was monitored spectrophotometrically at a 
340 nm every minute for up to 30 min. G6PDH, PK and LDH used in these assays were 
purchases from Sigma Aldrich (St. Louis, MO). 
GPI assay. The potential inhibitory effect of 2DG and 2DG6P on CpGPI was evaluated by a 
GPI/G6PDH-coupled assay as previously described (Eltahan et al. 2018). It was performed 
similarly to the HK/G6PDH-coupled assay, but in a reverse reaction direction that converted 
fructose-6P into glucose-6P by CpGPI. Glucose-6P was then converted into glucono-1,5-lactone-
6-phosphate by G6PDH using NAD+ as a cofactor. A typical assay was performed using 200 μL 
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reactions containing D-fructose-6P (2 mM), NAD+ (0.2 mM), G6PDH (2 U), MgCl2 (5 mM) in 
Tris.HCl buffer (50 mM, pH8.5), and MBP-CpGPI or MBP (50 ng). 
All assays were performed at least twice in triplicated reactions at room temperature (23 °C) 
except for the reactions involving HsHK1 enzyme that was assayed at 37 °C due to its low 
activity at room temperature. Enzyme kinetics were analyzed using GraphPad Prism version 5.0f 
or higher (http://www.graphpad.com). MBP-tag was used as the negative control in all assays for 
background subtraction.  
3.2.4 High-throughput (HTS) of screening of existing drugs 
 
The Prestwick chemical library containing 1200 existing drugs were screened in 96-well 
plates for potential anti-CpHK activities using the HK/G6PDH-coupled assay as described 
above. All drugs were screened at of 20 μM in primary screening. Each reaction was performed 
at least twice independently at room temperature. Negative controls using MBP-tag (2 
wells/plate) and positive controls using 2DG (5 mM; 2 wells/plate) were included in each plate. 
Top hits were then evaluated by G6PDH assay to exclude those showing significant anti-G6PDH 
activities from further analysis as described above. Hits with confirmed anti-CpHK activities 
were subjected to further analysis to determine their inhibitory kinetic parameters on CpHK in 
comparison with those of HsHK1. Because of the low activity of HsHK1 at room temperature, 
detailed comparison on the effects of inhibitors on CpHK and HsHK1 were performed at 37 °C. 
All reactions contained 1% DMSO that was used to increase the solubility of compounds and 
performed at least twice in triplicates. 
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3.2.5 Drug efficacy against the parasite growth in vitro 
 
The efficacies of 2DG, 2DG6P and hits identified from existing drugs were evaluated against 
the growth of C. parvum in vitro using a qRT-PCR assay as previously described (Cai et al. 
2005, Zhang and Zhu 2015, Guo et al. 2018). Briefly, HCT-8 cells (ATCC # CCL-225) were 
cultured overnight in 96-well plates in RPMI-1640 medium containing 10% fetal bovine serum 
(FBS) at 37 °C under 5% CO2 atmosphere until they reached to ~80% confluence. Oocysts were 
then added to the host cells monolayers (oocyst:host cell ratio = 1:2; i.e., ~2×104 oocysts with 
∼4×104 host cells/well) and incubated for 3 h at 37 °C, followed by a medium exchange to 
remove uninfected parasites and the addition of compounds at specified concentrations. Infected 
cells were incubated for an additional 41 h (total 44 h infection time). Cell lysates were prepared, 
diluted, and used directly to evaluate the parasite loads by qRT-PCR in 384-well plates as 
described (Zhang and Zhu 2015). Paromomycin (0.14 mM) and 2DG (0.5 mM) were used as 
positive controls and diluent (1% DMSO) is used as negative control in the assay. Cytotoxicity 
of drugs was evaluated by an MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) assay. In addition, the relative levels of 18S rRNA in uninfected HCT-8 cells was also 
evaluated for cytotoxicity. All assays were performed at least twice independently in triplicates. 
Data was analyzed with Microsoft Excel and GraphPad Prism version 5.0f or higher. 
 
3.3 Results 
 
 
3.3.1 The anti-cryptosporidial activity of 2-deoxy-D-glucose (2DG) was mainly attributed to 
its action on the parasite hexokinase (CpHK) 
 
We have previously shown that 2DG could inhibit CpHK enzyme activity (IC50 = 5.75 mM; 
Ki = 0.34 mM) and the growth of C. parvum (EC50 = 0.54 mM) at concentrations non-toxic to 
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host cells [104]. To fully understand the action of 2DG in the parasite, we wanted to determine 
whether CpHK could catalyze 2DG to form 2DG6P and whether 2DG6P could act on the 
downstream enzyme CpGPI to contribute to the anti-cryptosporidial activity. 
We first confirmed that, similar to HsHK1, CpHK could utilize 2DG as a substrate to form 
2DG6P (Km = 0.204 mM), but with ~4.5-fold lower affinity in comparison to its activity towards 
glucose (Km = 0.046 mM) (Table 2). The activities of CpHK on glucose and 2DG were 
comparable to HsHK1 (i.e., Km = 0.265 mM on 2DG and Km = 0.027 mM on glucose) (Table 2). 
The data also confirmed that the inhibition of 2DG on CpHK and HsHK1 was due to its direct 
competition with glucose and its action as a slow substrate of HKs.  
However, 2DG6P was infective on both CpHK and CpGPI at concentrations up to 28 mM 
(the maximal concentration achievable in the assay); while 2DG and its analog 
fluorodeoxyglucose (FDG) inhibited CpHK activity at low millimolar levels (IC50 = 5.75 mM 
and 3.7 mM, respectively), although 2DG and FDG were ineffective on CpGPI at concentrations 
up to 50 mM and 150 mM respectively (Table 3). For comparison, 2DG6P was also ineffective 
on HsHK1, whereas 2DG was effective on HsHK1 (IC50 = 5.75 mM) (Table 3). 
These observations were correlated well with the in vitro efficacy data on the parasite, in 
which 2DG and FDG inhibited the parasite growth at lower millimolar levels (EC50 = 0.54 mM 
and 0.30 mM, respectively), whereas 2DG6P could inhibit the parasite growth at concentrations 
of more than 33-fold higher than 2DG (i.e., EC50 = 18.0 mM) (Table 3). In contrast, host cells 
were much less sensitive to the inhibition of 2DG (TC50 = 36.0 mM; in vitro safety interval (SI) 
= 66.7), 2DG6P (TC50 >72.0 mM; SI >4.0) and FDG  (TC50 >72 mM; SI >240) (Table 4).  
Collectively, our data indicated that the anti-cryptosporidial activity of 2DG was mainly 
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attributed to the action of 2DG on CpHK, rather than the action of 2DG6P on CpGPI (Figure 
11). 
3.3.2 Four existing drugs were discovered to possess anti-CpHK activities 
 
As a first step to discover new CpHK inhibitors, we screened 1200 existing drugs in the 
Prestwick Chemical Library using an HK/G6PDH-coupled assay. The assay was validated by the 
NIH-recommended intra-plate, inter-plate, and inter-day uniformity tests.  Signal window (SW) 
and Z′ factor for each plate were calculated according to the Assay Guidance Manual as follows 
[159] 
SW=(AVGmax−3SDmax/n√)−(AVGmin+3SDmin/n√)SDmax/n√SW=(AVGmax-3SDmax∕n)- 
 
(AVGmin+3SDmin∕n)SDmax∕n 
 
  Z′=(AVGmax−3SDmax/n√)−(AVGmin+3SDmin/n√)AVGmax−AVGmin 
 
The SW and Z′ values in the nine plates were ranging from 7.1 to 37.59 and 0.70 to 0.92, 
respectively which are higher than the recommended acceptance criterions (i.e., SW ≥ 2 and Z′ ≥ 
0.4). Our primary screening identified 21 compounds with ≥ 50% inhibition of enzyme activity 
at 20 μM (Figure 7C). The 21 compounds were subjected to a G6PDH assay using lower 
concentrations of G6PDH (0.04 U) in the absence of CpHK and glucose, by which twelve 
compounds were confirmed to be specific. Among them, 8 hits were excluded for further assays 
due to cytotoxicity or insolubility at applicable concentrations. The remaining 4 specific CpHK 
inhibitors are thimerosal, alexidine dihydrochloride (alexidine•2HCl), hexachlorophene and 
ebselen (Figure 7B). 
Among the 4 hits, ebselen was previously found to also inhibit CpGPI [160]. However, 
other studies had showed that ebselen could act on as a reversible inhibitor of Plasmodium 
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falciparum HK (PfHK) or an irreversible inhibitor for Trypanosoma brucei HK (TbHK) [132, 
152], so that it was not a surprise to also see its inhibition on CpHK. We observed that, similar to 
its action on CpGPI and TbHK, ebselen was an irreversible inhibitor of CpHK, as the inhibition 
could not be reversed by up to 50-fold dilution of the inhibitor (i.e., from 100 to 2 μM) [132, 
160](Figure 10A). Additionally, the reducing agent DTT (dithiothreitol) at 100 mM could 
prevent the inhibition when incubated with the enzyme prior to the reaction and partially 
reversed the inhibition when added after incubation of ebselen with enzyme (Figure 10B). These 
observations suggest that ebselen might covalently bind to CpHK, likely via the modification of 
Cys residues of CpHK, while the direct contact between DTT and ebselen could interfere the 
enzyme-inhibitor association at certain levels. 
All four hits were further analyzed to determine their inhibitory kinetics and IC50 values 
on CpHK and HsHK. Ebselen (IC50 = 0.241 μM) and alexidine•2HCl (IC50 = 22.1 μM) acted as 
noncompetitive inhibitor of CpHK, while the action of thimerosal (IC50 = 2.3 μM) and 
hexachlorophene (IC50 = 8.8 μM) on CpHK fit with the mixed model of inhibition. They also 
showed very similar IC50 values on HsHK1 (Figure 8 ), suggesting no selectivity of the four 
compounds between CpHK and HsHK1. 
Despite of the lack of selectivity between the parasite and host HK enzymes, the four 
compounds affect the growth of C. parvum in vitro more that of the host cells. The in vitro 
safety intervals (SI; SI = TC50/EC50) ranged from ~4 for alexidine•2HCl and ebselen to 10.5 
for thimerosal and 188.7 for hexachlorophene, indicating that the parasite was much more 
sensitive than host cells to the inhibition by the four compounds, particularly by 
hexachlorophene (Table 5). 
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3.4 Discussion 
 
In the present study, we first confirmed that 2DG could be phosphorylated by CpHK to form 
2DG6P, but the phosphorylated form of 2DG was ineffective on CpGPI, CpHK and HsHK1 at 
concentrations comparable to or higher than the effective concentrations of 2DG (Table 2). 
2DG6P was much less effective than 2DG on the parasite grown in vitro and host cells (Table 4), 
which validated that the anti-cryptosporidial action of 2DG was attributed to its action on CpHK 
(Figure 11). These observations further support the notion that CpHK is a valid drug target in 
the parasite.  
As discussed earlier, the chance to develop 2DG into an anti-cryptosporidial therapeutic 
might be low, albeit further investigation [104]. However, 2DG can serve as a useful reagent to 
study the function of CpHK in the parasite. Because 2DG can be converted to 2DG6P, leading to 
the loss of inhibitory effect on the parasite, it would be highly appealing to design/identify 2DG 
analogs that cannot be phosphorylated by CpHK to extend its action on CpHK and increase its 
efficacy on the parasite. This notion is partly supported by the data on FDG that displayed 
slightly better anti-CpHK activity (IC50 = 3.7 mM on CpHK, vs. 5.75 mM by 2DG) (Table 3), 
and slightly improved in vitro anti-C. parvum efficacy (EC50 = 0.3 mM, vs. 0.54 mM by 2DG) 
and safety interval (>240-fold, vs. 66.7 for 2DG) (Table 4). 
Secondly, we initialized a drug screening campaign for identifying new anti-CpHK 
compounds by first screening 1200 existing drugs. Among the four anti-CpHK hits, only ebselen 
can be orally administrated for medical use [141, 143, 146, 161, 162] Ebselen (2-phenyl-1,2-
benzisoselenazol-3(2H)-one; CAS # 60940-34-3) is a synthetic organoselenium known to have 
multiple targets enzymes in many species including HKs from several protozoan parasites [131, 
132, 150-152, 163, 164]. It was also recently identified as the only inhibitor of CpGPI among 
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existing drug [160]. It is likely that ebselen might also affect other Cys-containing enzymes in 
the parasite. Although the efficacy of ebselen at micromolar levels was not impressive (EC50 = 
0.165 mM), there could be a chance to investigate its analogs to identify more efficacious and 
selective inhibitors.  
The other three hits were antiseptic biguanide (alexidine•2HCl), organochlorine 
(hexochlorophene) and organomercury (thimerosal) compounds [165, 166]. These compounds 
were also reported to possess activities against some parasites, such as the anti-Acanthamoeba 
activity of alexidine [167], anti-Plasmodium and anti-trypanosome activities of thimerosal [168, 
169], and anti-nematode and anti-protozoan activities of hexochlorophene [170-173]. On the 
other hand, these compounds are only labeled for use as vaccine preservative or disinfectants, 
rather than for oral medication, for which they are unlikely to be developed into anti-
cryptosporidial therapeutics. 
In summary, our study on the action of 2DG further supported that CpHK could serve as a 
drug target in the parasite, and the drug screening identified four existing drugs as CpHK 
inhibitors that could be used as new reagents for studying the CpHK enzyme properties. We are 
currently screening large compound libraries including the TimTec Diversity Screening Set of 
10,000 compounds (http://www.timtec.net) aimed to identify more efficacious and selective anti-
CpHK leads for developing anti-cryptosporidial therapeutics, and will report our findings in the 
near future. 
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Table 2 CpHK and HsHK1 enzyme parameters towards D-glucose and 2-deoxy-D-glucose 
(2DG) as determined by HK/G6PDH-coupled assay 
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Table 3 Effects of 2-deoxy-D-glucose (2DG), 2-deoxy-D-glucose-6-phosphate (2DG6P) and 
fluorodeoxyglucose (FDG) on CpHK, HsHK1 and CpGPI enzyme activities 
 
 
 
 
 
 
Table 4 In vitro efficacy of 2-deoxy-D-glucose (2DG), 2-deoxy-D-glucose-6-phosphate (2DG6P) 
against the growth of C. parvum (44 h infection assay) and cytotoxicity on the HCT-8 cells (44 h 
treatment) 
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Figure 7 Identification of four drugs as 
 inhibitors of CpHK from existing drugs of 
Prestwick chemical library 
 
 
D Illustration on the assay strategies to determine 
the CpHK enzyme activities on glucose (A) or 
other hexoses such as fructose, mannose and 2-
deoxy-glucose (B). (C) Screening of the 
Prestwick chemical library containing 1,200 
existing drugs at 20 μM (open round circles). 
Nineteen are identified with > 50 % enzyme 
inhibition (closed circles). Fourteen of the drugs 
are CpHK specific from which four candidates 
are identified (open triangles). (D) Hit 
validation assay showing four authentic hits 
because they were ineffective on G6PDH used 
in the CpHK/G6PDH-coupled assay, with no 
inhibition on G6PDH. Bars represent standard 
errors of the mean (SEMs) derived from at least 
three replicated reactions. 
 
 
C 
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Figure 8 Dose-dependent inhibition of drug candidates on CpHK (left panel) and HsHK1(Right panel) 
for determining the IC50 values. Bars represent standard errors of the mean (SEMs) derived from at least 
three replicated reactions. 
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Figure 9 Allosteric kinetics of the drug kinetics with CpHK (A) Apparent kinetics of thimerosal and 
hexachlorophene fitted with the competitive inhibition model; (B) Alexidine dihydrochloride and ebselen 
fitted with the non-competitive inhibition model. Bars represent standard errors of the mean (SEMs) 
derived from at least three replicated reactions. 
 
A B 
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Figure 10  Effects of dilution and DTT on the inhibition of ebselen (Ebs) on CpHK 
(A) In the inhibitor dilution assay, pre-incubation of ebselen (100 μM) with CpHK on ice for 10 min 
followed by 50-fold dilution with the addition of other reaction components had no effect on the 
inhibition of ebselen on CpHK (B) In the DTT assay, pre-incubation of DTT (100 mM) and CpHK only 
slightly affected the enzyme activity (lane 2), but blocked the inhibition of ebselen on CpHK (lane 4). 
DTT partially reversed ebselen inhibition without its prior incubation with CpHK (lane 5). Bars represent 
standard errors of the mean (SEMs) derived from at least three replicate d reactions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
- 
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Table 5 Inhibition of the CpHK and HsHK1 enzyme activity by the top four hits identified from 
1200 existing drugs and their efficacies against the growth of C. parvum in vitro 
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Figure 11 Potential action of 2DG in C. parvum cell leading to the inhibition of parasite growth 
by blocking the glycolysis. 2DG inhibited CpHK and HsHK1 (solid lines) but was ineffective on 
CpGPI up to 50 mM (dotted lines). 2DG6P was ineffective (dotted lines) against CpGPI, CpHK 
and HsHK up to 28 mM.  
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4 SUMMARY AND CONCLUSIONS 
 
Cryptosporidium parvum is a unicellular protozoan that infects wide range of host including 
humans and other animals. It is one of the top 4 diarrheal pathogens in children in developing 
countries in which they suffer from growth retardation and also associated with fatalities in 
toddlers. The preventative measures are not fully effective and the treatment options are limited. 
Up to date, Nitazoxanide (NTZ) is the only FDA-approved drug for use in immunocompetent 
patients with no treatment yet for animals. Although, HAART therapy can be provided for 
treatment of cryptosporidiosis in immunocompromised patients but it is life threatening. 
Therefore, there is a strong urge to develop new and effective anti-cryptosporidial drugs. 
 Fortunately, the whole genome of C. parvum is sequenced revealing the unique metabolic 
features of C. parvum. It lacks the mitochondria genome and apicoplast, unlike other 
apicomplexans examined so far. Since, it lacks the TCA (krebs cycle) and cytochrome-based 
respiration, it relies mainly, if not only, on glycolysis for energy source. It also lacks the denovo 
synthetic pathways (amino acids, fatty acids and nucleotides) so it lacks various pathways that 
serves as potential drug targets in other apicomplexans. Therefore, it is worth exploring the 
glycolytic enzymes as potential drug targets for developing novel therapeutics. 
In this study, we characterized the primary biochemical features of the glycolytic enzyme, C. 
parvum glucose-6-phosphate isomerase (CpGPI). By high-throughput screening of 1,200 known 
drugs using spectrophotometer based- assays, we discovered ebselen, was an inhibitor of CpGPI. 
Ebselen acted on CpGPI as an allosteric noncompetitive inhibitor. We also identified thimerosal, 
hexachlorophene, alexidine dihydrochloride and ebselen as CpHK inhibitors. Thimerosal and 
hexachlorphene acted as competitive inhibitors, while alexidine dihydrochloride and ebselen 
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were noncompetitive inhibitors of CpHK. The four drugs can also inhibit the growth of C. 
parvum in vitro at concentrations nontoxic to host cells by qRT-PCR. Additionally, ebselen 
might also target other enzymes in the parasite, leading to the parasite growth reduction. 
Collectively, the discovery of these drugs as selective CpGPI/CpHK inhibitors provides an 
opportunity to study the properties of the enzymes and its enzyme-inhibitor interactions. This 
study also provides a basis for the further screening of large compound libraries to identify new 
chemical structures as inhibitors for potential development as anti-cryptosporidial therapeutics. 
Added to this, CpGPI is a “plant-like” and CpHK is a “bacterial-like” enzyme which are highly 
divergent from those in mammals [13, 104]. There is a good opportunity to identify more 
selective and more potent enzyme inhibitors for humans and other mammals with greater safety 
intervals.  
Moreover, our previous study revealed 2-deoxy-D-glucose (2DG) can inhibit CpHK and C. 
parvum growth invitro but the potential mechanism of action is not yet clear. This study showed 
2DG was at least 30 folds more potent than 2-deoxy-D-glucose-6 phosphate (2DG6P). Together 
with inability of 2DG6P to inhibit both, CpGPI and CpHK enzymes, our study suggests the 
inhibitory effect of 2DG on the parasite growth is mostly attributed to its inhibition on CpHK 
rather than by its metabolizable product, 2DG6P. It may be rewarding to explore 2DG, 
previously investigated as anti-viral and anti- cancerous agent in clinical trials, as a new 
therapeutic drug for cryptosporidiosis. Also, this study will open avenues to study other and 
possibly more potent sugar analogues with anti-cryptosporidial activities. Therefore, although the 
2DG and the drug candidates are useful in studying the inhibition of CpGPI and CpHK enzyme 
activities, further proof is needed to chemically and/or genetically validate both enzymes as drug 
targets. 
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